Podcast
Questions and Answers
Which non-insulin T2DM therapy is expected to have the greatest A1c-lowering effect?
Which non-insulin T2DM therapy is expected to have the greatest A1c-lowering effect?
- Tirzepatide
- Exenatide
- Lixisenatide
- Dulaglutide (correct)
What is the difference between Ozempic and Rybelsus, since both are semaglutide?
What is the difference between Ozempic and Rybelsus, since both are semaglutide?
- Rybelsus is a rapid-acting insulin; Ozempic is a long-acting insulin
- Rybelsus is injectable; Ozempic is the oral version for T2DM
- Rybelsus is for T1DM; Ozempic is for T2DM
- Rybelsus is the oral version for T2DM; Ozempic is injectable (correct)
Which non-insulin T2DM therapies are injected by the patient?
Which non-insulin T2DM therapies are injected by the patient?
- Empagliflozin
- Dulaglutide
- Liraglutide (correct)
- Metformin
Which T2DM therapies can be combined?
Which T2DM therapies can be combined?
Which drugs are currently approved for pediatric patients with Type 2 DM?
Which drugs are currently approved for pediatric patients with Type 2 DM?
Which patients need to monitor their BG more frequently?
Which patients need to monitor their BG more frequently?
Why do patients with CGM still need a monitoring device with test strips to check their BG with a fingerstick glucose?
Why do patients with CGM still need a monitoring device with test strips to check their BG with a fingerstick glucose?
Which type of glucose-lowering medication is usually used for treatment of T2DM for a patient who is pregnant?
Which type of glucose-lowering medication is usually used for treatment of T2DM for a patient who is pregnant?
Which GLP1-RA is approved for pediatric patients with Type 2 DM?
Which GLP1-RA is approved for pediatric patients with Type 2 DM?
Which non-insulin T2DM therapy is not expected to have the greatest A1c-lowering effect?
Which non-insulin T2DM therapy is not expected to have the greatest A1c-lowering effect?
Which non-insulin T2DM therapy is injectable and can be combined with basal insulin?
Which non-insulin T2DM therapy is injectable and can be combined with basal insulin?
Which non-insulin T2DM therapy is not injected by the patient?
Which non-insulin T2DM therapy is not injected by the patient?
Which non-insulin T2DM therapy is available in an oral version for T2DM?
Which non-insulin T2DM therapy is available in an oral version for T2DM?
Which non-insulin T2DM therapy is a DPP4 inhibitor?
Which non-insulin T2DM therapy is a DPP4 inhibitor?
Which non-insulin T2DM therapy is not a GLP1-RA?
Which non-insulin T2DM therapy is not a GLP1-RA?
Which non-insulin T2DM therapy is not expected to have the greatest A1c-lowering effect?
Which non-insulin T2DM therapy is not expected to have the greatest A1c-lowering effect?
Which non-insulin T2DM therapy is a GLP1-RA and can be combined with metformin?
Which non-insulin T2DM therapy is a GLP1-RA and can be combined with metformin?
Which non-insulin T2DM therapy is not expected to have the greatest A1c-lowering effect?
Which non-insulin T2DM therapy is not expected to have the greatest A1c-lowering effect?
Which non-insulin T2DM therapy is associated with a black box warning for thyroid C cell tumors in rats?
Which non-insulin T2DM therapy is associated with a black box warning for thyroid C cell tumors in rats?
Which non-insulin T2DM therapy has a potential risk of dehydration and necrotizing fasciitis of the genitals as adverse effects?
Which non-insulin T2DM therapy has a potential risk of dehydration and necrotizing fasciitis of the genitals as adverse effects?
Which non-insulin T2DM therapy is associated with a risk of lactic acidosis and vitamin B deficiency as adverse effects?
Which non-insulin T2DM therapy is associated with a risk of lactic acidosis and vitamin B deficiency as adverse effects?
Which non-insulin T2DM therapy is known for its potential risk of pancreatitis and gallstones?
Which non-insulin T2DM therapy is known for its potential risk of pancreatitis and gallstones?
Which non-insulin T2DM therapy is associated with a black box warning for severe joint pain and a potential risk of heart failure?
Which non-insulin T2DM therapy is associated with a black box warning for severe joint pain and a potential risk of heart failure?
Which non-insulin T2DM therapy is known for its potential risk of AKI (acute kidney injury) and bowel obstruction/worsening gastroparesis?
Which non-insulin T2DM therapy is known for its potential risk of AKI (acute kidney injury) and bowel obstruction/worsening gastroparesis?
Which non-insulin T2DM therapy has a potential risk of hypoglycemia and weight gain as adverse effects?
Which non-insulin T2DM therapy has a potential risk of hypoglycemia and weight gain as adverse effects?
Which non-insulin T2DM therapy is associated with a potential risk of DKA (diabetic ketoacidosis) and sulfa allergy?
Which non-insulin T2DM therapy is associated with a potential risk of DKA (diabetic ketoacidosis) and sulfa allergy?
Which non-insulin T2DM therapy is known for its potential risk of liver toxicities and bladder cancer?
Which non-insulin T2DM therapy is known for its potential risk of liver toxicities and bladder cancer?
Which non-insulin T2DM therapy has a potential risk of GI (gastrointestinal) adverse effects such as N/V/D (nausea, vomiting, diarrhea) and abdominal pain?
Which non-insulin T2DM therapy has a potential risk of GI (gastrointestinal) adverse effects such as N/V/D (nausea, vomiting, diarrhea) and abdominal pain?
